Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 30, 2026.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]

Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.

The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced seizure-related hospitalizations among people with drug-resistant epilepsy receiving vagus nerve stimulation therapy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.